事实证据 1
收购Chinook
暂无可公开的证据摘要。
钛媒体 · 2026-10-09 14:53
查看证据
- 媒体钛媒体2026-10-09 14:53查看来源
NOVN SIX
Novartis
简介
NOVN · SIX诺华製藥集團 通稱諾華（Novartis），是一間总部位于瑞士巴塞尔的跨国制药及生物技术公司。它的核心业务为各种专利药、消费者保健、非专利药、眼睛护理和动物保健等领域。诺华公司成立于1996年，由位于巴赛尔的两家化学品及制药公司“汽巴-嘉基”（Ciba-Geigy）和“山德士”（Sandoz）合并而成。
Wikipedia · CC BY-SA 4.0
- 总部
- CH
- 官网
- 官网
Novartis 的结构
Novartis
公司
15 个关联
归属投资与持股1 / 2
上游供应与依赖2 / 3
约束监管与敞口3 / 5
下游客户
自有产品与技术2 / 3
关系出现时间
Novartis公司 · 15 个关联
第 1 层上游供应与依赖2
下游客户7
归属投资与持股1
自有产品与技术2
约束监管与敞口3
关系
箭头表示关系方向，可按业务类别筛选。
- 事实90%
查看证据
- 公司披露GlobeNewswire public company news2026-10-07 19:00
In multiple sclerosis (MS), Novartis has helped shape the treatment landscape for decades through scientific innovation and leadership in advancing care for people living with MS.
查看来源
- 产业 · Neurology证据 1事实90%
查看证据
- 公司披露GlobeNewswire public company news2026-10-07 19:00
Building on this foundation, we're doubling down on our commitment to neurology, expanding our legacy of innovation in MS and spinal muscular atrophy (SMA) to work in neuroimmunology, neurodegeneration, and neuromuscular diseases.
查看来源
- 事实90%
查看证据
- 公司披露GlobeNewswire public company news2026-10-07 19:00
Building on this foundation, we're doubling down on our commitment to neurology, expanding our legacy of innovation in MS and spinal muscular atrophy (SMA) to work in neuroimmunology, neurodegeneration, and neuromuscular diseases.
查看来源
- 事实90%
查看证据
- 公司披露GlobeNewswire public company news2026-10-07 19:00
Building on this foundation, we're doubling down on our commitment to neurology, expanding our legacy of innovation in MS and spinal muscular atrophy (SMA) to work in neuroimmunology, neurodegeneration, and neuromuscular diseases.
查看来源
- 事实90%
查看证据
- 公司披露GlobeNewswire public company news2026-10-07 19:00
Building on this foundation, we're doubling down on our commitment to neurology, expanding our legacy of innovation in MS and spinal muscular atrophy (SMA) to work in neuroimmunology, neurodegeneration, and neuromuscular diseases.
查看来源
- 事实90%
查看证据
- 公司披露GlobeNewswire public company news2026-10-07 19:00
Building on this foundation, we're doubling down on our commitment to neurology, expanding our legacy of innovation in MS and spinal muscular atrophy (SMA) to work in neuroimmunology, neurodegeneration, and neuromuscular diseases.
查看来源
- 事实90%
查看证据
- 公司披露GlobeNewswire public company news2026-10-07 19:00
In particular, our expectations could be affected by, among other things, uncertainties concerning: global healthcare cost containment
查看来源
- 事实90%
查看证据
- 公司披露GlobeNewswire public company news2026-10-07 19:00
ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency
查看来源
显示第 1 至 8 条，共 20 条
结论
结合来源阅读结论，展开条目查看证据。
事实证据 1
暂无可公开的证据摘要。
钛媒体 · 2026-10-09 14:53
查看证据
- 媒体钛媒体2026-10-09 14:53查看来源
事实证据 1
暂无可公开的证据摘要。
钛媒体 · 2026-10-09 14:53
查看证据
- 媒体钛媒体2026-10-09 14:53查看来源
事实证据 1
people reached by its medicinesmore than 300 million people
Our medicines reach more than 300 million people worldwide.
GlobeNewswire public company news · 2026-10-07 19:00
查看证据
- 公司披露GlobeNewswire public company news2026-10-07 19:00
Our medicines reach more than 300 million people worldwide.
查看来源
事实证据 1
ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency
GlobeNewswire public company news · 2026-10-07 19:00
查看证据
- 公司披露GlobeNewswire public company news2026-10-07 19:00
ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency
查看来源
事实证据 1
In particular, our expectations could be affected by, among other things, uncertainties concerning: global healthcare cost containment
GlobeNewswire public company news · 2026-10-07 19:00
查看证据
- 公司披露GlobeNewswire public company news2026-10-07 19:00
In particular, our expectations could be affected by, among other things, uncertainties concerning: global healthcare cost containment
查看来源
显示第 1 至 6 条，共 23 条
市场与估值
估值数据需要 Pro 或 Research。
升级到 Pro 解锁暂无: 公司信号 · 财务数据 · 披露文件 · 业绩指引